Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2360974 | 0.92 | ALDH1A1 (0.84) | ALDH1A1PKMKMT2AMEN1POLB | |
| SCHEMBL5347059 | 0.86 | ALDH1A1 (0.97) | ALDH1A1PKMKMT2AMEN1POLB | |
| SCHEMBL2061369 | 0.85 | PKM (0.76) | ALDH1A1PKMKMT2AMEN1POLB | |
| SCHEMBL28137833 | 0.84 | ALDH1A1 (1.00) | ALDH1A1PKMKMT2AMEN1POLB | |
| SCHEMBL17007463 | 0.83 | ALDH1A1 (0.75) | ALDH1A1PKMKMT2AMEN1POLB | |
| SCHEMBL7647475 | 0.83 | ALDH1A1 (0.75) | ALDH1A1PKMKMT2AMEN1POLB | |
| SCHEMBL14256511 | 0.82 | PKM (0.72) | ALDH1A1PKMKMT2AMEN1POLB | |
| Hydrochloric Acid SCHEMBL6094287 | 0.82 | POLB (0.69) | ALDH1A1PKMKMT2AMEN1POLB | |
| SCHEMBL2062534 | 0.82 | POLB (0.75) | ALDH1A1PKMKMT2AMEN1POLB | |
| SCHEMBL31234627 | 0.82 | POLB (0.75) | ALDH1A1PKMKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2275404-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | ALDH1A1 180/4885PKM 4306/4885KMT2A 2852/4885 |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | BHMT, CBS, BHMT2 | ALDH1A1 600/4885PKM 2586/4885KMT2A 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.